FDA Guidance on Treatments for Renal Cell Carcinoma
The agency published recommendations for the development of drugs and biologics for the adjuvant treatment of renal cell carcinoma.
FDA published guidance on October 1, 2020 regarding the development of drugs and biologics for the adjuvant treatment of renal cell carcinoma. Eligibility criteria, choice of comparator, follow-up imaging assessments, determination of disease recurrence, analyses of disease-free survival (DFS), and interpretation of trial results are discussed in the guidance document. According to FDA, the guidance is focused on clinical trials with DFS as the primary efficacy endpoint.
The guidance states that, “Significant variability exists in the design, conduct, and analysis of trials for the adjuvant treatment of renal cell carcinoma, including the eligibility criteria, radiological disease assessments, the definition of disease recurrence, and the date used to define the DFS endpoint. Consistency in these aspects within and across trials may facilitate interpretation of trial results.”
Source: FDA
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
